GlassScriptPhysician profile
Mehdi Ferdows
NPI 1518960616
$18,283.00
in general payments reported to CMS, 2019-2025
40 companies · $3,553 in 2025
The $3,553 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,250 · 2020: $1,785 · 2021: $2,785 · 2022: $2,640 · 2023: $2,576 · 2024: $2,693 · 2025: $3,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,606 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,605.60 |
| Education | $216.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,137.80 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,884.48 | 2019-2025 | Xifaxan, Plenvu, Relistor |
| Janssen Biotech, INC. | $1,567.80 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $1,334.59 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,279.65 | 2019-2025 | Entyvio, Gattex |
| Nestle Healthcare Nutrition INC. | $961.44 | 2020-2023 | |
| Celgene Corporation | $928.02 | 2021-2024 | Zeposia |
| Fujifilm Healthcare Americas Corporation | $803.16 | 2020-2021 | |
| Genzyme Corporation | $801.94 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $801.44 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $655.72 | 2019-2025 | |
| Daiichi Sankyo INC. | $403.58 | 2019-2025 | Injectafer |
| Madrigal Pharmaceuticals | $400.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $388.08 | 2023-2025 | Omvoh |
| Braintree Laboratories, INC. | $231.16 | 2019-2025 | Suflave, Sutab |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $164.97 | 2024-2025 | Dupixent, Libtayo |
| Shionogi INC | $141.77 | 2019 | |
| Ferring Pharmaceuticals INC. | $134.41 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $130.10 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $127.80 | 2023-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $121.99 | 2020-2025 | |
| Organon LLC | $110.50 | 2023-2024 | Hadlima, Renflexis |
| Ipsen Biopharmaceuticals, INC | $90.31 | 2024-2025 | Iqirvo, Bylvay |
| Allergan, INC. | $68.26 | 2019-2020 | |
| Ardelyx, INC. | $67.71 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $66.59 | 2023-2024 | Zymfentra, Yuflyma |
| Digestive Care, INC. | $59.15 | 2021-2022 | |
| Novo Nordisk INC | $58.92 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $53.70 | 2023 | Idacio |
| Merck Sharp & Dohme LLC | $50.72 | 2019 | |
| Ucb, INC. | $39.40 | 2019-2020 | |
| Orphalan INC | $35.28 | 2025 | Cuvrior |
| Olympus America INC. | $27.98 | 2019 | |
| Amgen INC. | $25.81 | 2023 | Avsola, Amjevita |
| Amag Pharmaceuticals, INC. | $25.54 | 2019-2022 | |
| Exact Sciences Corporation | $24.58 | 2025 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $23.71 | 2019-2020 | |
| Boston Scientific Corporation | $19.12 | 2020 | |
| Redhill Biopharma INC. | $18.29 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.77 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehdi Ferdows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.